

厚生労働科学研究費補助金（肝炎等克服緊急対策研究事業）  
分担研究報告書

分子標的創薬に向けた細胞内活性化ネットワークの推定研究

堀本 勝久 産業技術総合研究所 研究チーム長

**研究要旨：**分子標的創薬に貢献するため、2つの実用的な標的分子探索法を開発した。一つは、特異的条件下活性化しているタンパク質相互作用ネットワークを推定する方法で、もう一つは、予後データや検体サンプルの特徴などの表現型から分子機能を推定する方法である。肝炎の分子メカニズムに関する知見が蓄積していることを鑑み、前者は活性化ネットワークのデータ駆動型の推定と異なり、既知ネットワーク群から計測データとの整合性を示すネットワークを抽出することで活性化ネットワークを探索する知識駆動型の方法である。また後者は、通常分子データの統合により表現型を推定するボトムアップ型とは異なり、予後データで規定されるサンプルの特徴から分子機能を推定するトップダウン型の方法である。またこれら方法は、単一標的候補分子の絞り込みによるドロップの危険性回避、標的候補分子に関する薬効の作用・副作用メカニズムの推定などに有用であり、実験主導創薬と相補的な役割を担う。

A. 研究目的

実応用可能な分子標的創薬に貢献する数理解析手法の開発を目的とした。特に、分子標的薬の標的分子及び薬効メカニズムの推定を可能とするネットワーク解析法を開発する。これら解析法の開発は、創薬過程における、単一標的候補分子の絞り込みによるドロップの危険性回避や標的候補分子に関する薬効の作用・副作用メカニズムの推定などに有用であり、実験主導創薬と相補的な役割を担うことが期待される。

B. 研究方法

2つの実用的な標的分子解析法を開発した。一つは、特異的条件下活性化している分子相互作用ネットワークを推定する方法

で、もう一つは、予後データや検体サンプルの特徴などの表現型から分子機能を推定する方法である。肝炎の分子メカニズムに関する知見が蓄積していることを鑑み、前者は活性化ネットワークのデータ駆動型の推定と異なり、既知ネットワーク群から計測データとの整合性を示すネットワークを抽出することで活性化ネットワークを探索する知識駆動型の方法である。また後者は、通常分子データの統合により表現型を推定するボトムアップ型とは異なり、予後データで規定されるサンプルの特徴から分子機能を推定するトップダウン型の方法である。

（倫理面への配慮）

当機関においては、数理研究のみを実施するため、動物実験等の該当は無い。

## C. 研究結果

本研究の目的が方法開発であることを鑑み、その有用性の公正な評価を行うため、標的分子や薬効メカニズムが既知の、糖尿病及び肺がんに関するオープンソースを利用して解析をまず実行した。その後、肝炎関連新規計測データに関して解析を実行した。肝炎関連データに関しては、非環式レチノイド投与に関する遺伝子発現サンプル 24 サンプル（臨床背景：再発有 12 サンプル、無 12 サンプル）の 8516 プローブについて表現型指向解析法を適用し、非環式レチノイド投与後の再発に関与する 37 遺伝子セットをその分子メカニズム候補として推定し、さらに活性化ネットワーク推定法によりそれらセットに含まれる遺伝子群から 47 遺伝子を再発要因遺伝子として同定した。

## D. 考察

表現型相異指向解析法及び活性化ネットワーク推定法によって同定された候補遺伝子の検証は、最終的には実験検証が必要であるが、これらの解析により 3 遺伝子のみが“cytokines and growth factors”であるなど、実験検証可能な少数分子候補への絞り込みの可能性を示すことができた。

## E. 結論

本研究において開発された、表現型相異指向解析による分子 signature の推定、それに続く活性化ネットワーク推定により、少数標的分子候補及び薬効メカニズムの推定が可能な数理解析プラットフォームを構

築する事ができた。

## F. 研究発表

### 1. 論文発表

- 1) Piao, G., Saito, S., Sun, Y., Liu, Z., Wang, Y., Han, X., Wu, J., Zhou, H., Chen, L. and Horimoto, K.: A computational procedure for identifying master regulator candidates for diabetes progression in Goto-Kakizaki rat, BMC Sys. Biol., 6(Suppl1), S2, 2012
- 2) Zhou, H., Saito, S., Hu, R., Piao, G., Wang, J., Liu, Z., Horimoto, K. and Chen, L.: Network Screening of Goto-Kakizaki Rat Liver Microarray Data during Diabetic Progression. BMC Sys. Biol. 5(Suppl 1), S16, 2011.
- 3) Nakatsu, M., Horimoto, K., Lemaire, F., Ürgüplü, A., Sedoglavic, A. and Boulier, F.: Brute force meets Bruno force in parameter optimization: Introduction of novel constraints for parameter estimation by symbolic computation. IET Sys. Biol., 5, 281–292, 2011.
- 4) Saito, S., Hirokawa, T. and Horimoto, K.: Discovery of Chemical Compound Groups with Common Structures by a Network Analysis Approach. J. Chem. Inf. Model. 51, 61-68, 2011

### 2. 学会発表

- 1) Horimoto, K.: A practical approach to define the candidates of key molecules responsible for biological phenomena: in the cases of iPS cell and a few disease studies. Key Laboratory of Systems Biology, SIBS, CAS - International Outstanding Scientist

Lecture Series, August, 12, 2011, Shanghai, China.

- 2) Horimoto, K.: On Two Issues of Molecular Network Models in Systems Biology – A Review, The 10th International Symposium on Operations Research and its Applications in engineering, technology and management (ISORA 2011), August 28, 2011, Dunhang, China.
- 3) 堀本勝久：「創薬のための計算システム生物学」シンポジウム「第3回新たな創薬パラダイムの創出」、2012年1月12日、東京大学医科学研究所1号館講堂
- 4) Saito, S., Nagamatsu, G., Zhou, H., Horimoto, K.: Phenotype-Difference Oriented Analysis for Detecting Molecular Functions from Omics Data. The Fourth Annual International Conference on Computational and Systems Biology (ICCSB2012), SHANGHAI – CHINA October 12-14, 2012.

G. 知的所有権の出願・取得状況

1. 特許取得

なし

2. 実用新案登録

なし

3. その他

特になし

### III. 研究成果の刊行に関する一覧表

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Yamashita T, (金子)	Differentiation of Cancer Stem Cells	Stanley Shostak	Cancer Stem Cells - The Cutting Edge	InTech	Croatia	2011	337-350
Yamashita T, (金子)	Heterogeneity of Liver Cancer Stem Cells.	Xin W. Wang Joe W. Grisham Snorri S. Thorgeirsson	Molecular Genetics of Liver Neoplasia	Springer	New York	2010	301-318
飯田健夫、菅裕明	RaPIDシステムによる特殊ペプチド薬剤の探索		フロンティア22：生命現象を理解する分子ツール	化学同人		2010	71-76
樋口岳、菅裕明	擬天然物特殊ペプチドのプログラム合成と応用		有機合成化学協会誌			2010	68, 217-227
林剛介、大城幸紀、菅裕明	特殊環状ペプチドの翻訳合成と医薬品探索への展開		生化学			2010	6, 505-514
後藤佑樹、伊東利紗、菅裕明	RaPIDシステムが拓く新創薬戦略		MEDCHEM NEWS			2010	No. 4 26-31
Nakatsui M, (堀本)	A General Procedure for the Accurate Parameter Estimation in Dynamic Systems Using New Estimation Errors.	Horimoto, K. Nakatsui, M., Popov, N.	Algebraic and Numeric Biology	Springer	Heidelberg	2012	149-166

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Yamashita T, (金子)	Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma.	Hepatology	-	-	(in press)
Mizukoshi E, (金子)	Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.	Hepatology	-	-	(in press)

Mizuno H, (金子)	Heterogeneous nuclear ribonucleoprotein A2/B1 in association with hTERT is a potential biomarker for hepatocellular carcinoma.	Liver Int	32(7)	1146-1155	2012
Mizukoshi E, (金子)	Expression of chondroitin-glucuronate C5-epimerase and cellular immune responses in patients with hepatocellular carcinoma.	Liver Int	32(10)	1516-1526	2012
Okada H, (金子)	Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development.	Cancer Res	72(17)	4459-4471	2012
Kitao A, (金子)	Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images.	Radiology	265(3)	780-789	2012
Oishi N, (金子)	Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.	Hepatology	56(5)	1792-1803	2012
Shugo H, (金子)	Nucleostemin in injury-induced liver regeneration.	Stem Cells Dev	21(16)	3044-3054	2012
Yamashita T, (金子)	Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection.	J Gastroenterol Hepatol	26(6)	960-964	2011
Sunagozaka H, (金子)	Identification of a secretory protein c19orf10 activated in hepatocellular carcinoma.	Int J Cancer	129(7)	1576-1585	2011
Nakamoto Y, (金子)	Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.	Clin Exp Immunol	163(2)	165-177	2011
Yamashita T, (金子)	Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.	Cancer Res	70(11)	4687-4697	2010
Takatori H, (金子)	dUTP pyrophosphatase expression correlates with a poor prognosis in hepatocellular carcinoma.	Liver Int	30(3)	438-446	2010
Hodo Y, (金子)	Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma.	Genomics	95(4)	217-223	2010



Fumihiko Y, (小原)	Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.	J Med Virol	-	-	(in press)
Makoto S, (小原)	Hepatitis C virus induces overexpression of 3 $\beta$ -hydroxysterol $\Delta$ 24-reductase through Sp1.	J Med Virol	84	733-746	2012
Yuichi H, (小原)	Self-enhancement of Hepatitis C Virus Replication by Promotion of Specific Sphingolipid Biosynthesis.	PLoS Pathog	8(8)	e1002860	2012
Kazuaki I, (小原)	Impairment of interferon regulatory factor-1 3 activation by hepatitis C virus core protein basic region 1.	Biochem Biophys Res Commun	428(4)	494-499	2012
Satoshi S, (小原)	Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver.	PLoS One	7(12)	e51656	2012
Kasama Y, (小原)	Translocase of outer mitochondrial membrane 70 induces interferon response and is impaired by hepatitis C virus NS3.	Virus Res	163	405-409	2012
Weng L, (小原)	Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase.	Gene	496	79-87	2012
Konishi H, (小原)	An orally available, small-molecule interferon inhibits viral replication.	Sci Rep	259	1-9	2012
Arai M, (小原)	Establishment of infectious HCV virion-producing cells with newly designed full-genome replicon RNA.	Arch Virol	156	295-304	2011
Takano T, (小原)	Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes.	J Hepatology	55	512-521	2011
Takano T, (小原)	Translocase of outer mitochondrial membrane 70 is induced by hepatitis C virus and is related to the apoptotic response.	J Med Virol	83	801-809	2011
Kimura K, (小原)	Role of interleukin-18 in intrahepatic inflammatory cell recruitment in acute liver injury.	Journal of Leukocyte Biology	89	433-442	2011

Yoshikawa K, (小原)	Incorporation of biaryl units into the 5' and 3' ends of sense and antisense strands of siRNA duplexes improves strand selectivity and nuclease resistance.	Bioconjugate Chemistry	22	42-49	2011
Kimura K, (小原)	Frontiers of Model Animals for Human Diseases.	Experimental Animals	60(2)	93-100	2011
Chiyo T, (小原)	Conditional hepatitis C virus gene expression without induction of severe inflammatory responses through the use of a Cre-expressing recombinant adenovirus in mice.	Virus Res	160	89-97	2011
Satoh M, (小原)	Monoclonal antibody 2-152a suppresses hepatitis C virus infection through betaine/GABA transporter-1.	J Infect Dis	204	1172-1180	2011
Amako Y, (小原)	Pathogenesis of hepatitis C virus infection in <i>Tupaia belangeri</i> .	J Virology	84(1)	303-311	2010
Satoh H, (小原)	Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice.	J Med Virol	82(9)	1545-1553	2010
Kasama Y, (小原)	Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas <i>in vivo</i> .	Blood	116(23)	4926-4933	2010
Nuriya H, (小原)	Detection of hepatitis B and C viruses in almost all hepatocytes by modified PCR-based <i>in situ</i> hybridization.	J Clin Microbiol	48(11)	3843-3851	2010
Weng L, (小原)	Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype specific manner.	J Virology	84(22)	11761-11770	2010
K. Iwasaki, (菅)	Selective thioether macrocyclization of peptides having the N-terminal 2-chloroacetyl group and competing two or three cysteine residues in translation.	Organic & Biomolecular Chemistry	10	5783-5786	2012
Y. Hayashi, (菅)	In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors.	ACS Chemical Biology	7	607-613	2012
C. J. Hipolito, (菅)	Ribosomal production and in vitro selection of natural product-like peptidomimetics: The FIT and RaPID systems.	Current Opinion in Chemical Biology	16	196-203	2012



Y. Yamagishi, (菅)	Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library.	Chemistry&Biology	18	1562-1570	2011
Y. Ohshiro, (菅)	Ribosomal synthesis of backbone-macrocyclic peptides containing $\gamma$ -amino acids.	ChemBioChem	12	1183-1187	2011
J. Chung, (菅)	Small-molecule inhibitor binding to an N-acyl-homoserine lactone synthase.	Pro Nat Acad Sci	108(29)	12089-12094	2011
K. Öjemalm, (菅)	Apolar surface area determines the efficiency of translocon-mediated membrane-protein integration into the endoplasmic reticulum.	Pro Nat Acad Sci	108(31)	E359-364	2011
J. Morimoto, (菅)	Flexizymes: Their evolutionary history and the origin of catalytic function.	Accounts of Chemical Research	44(12)	1359-1368	2011
T. Katoh, (菅)	Ribosomal synthesis of backbone macrocyclic peptides.	Chemical Communication	47	9946-9958	2011
Y Goto, (菅)	Flexizymes for genetic code reprogramming.	Nature Protocols	6	779-790	2011
T-J Kang, (菅)	Synthesis of a Backbone-cyclic Peptide SFTI-1 Promoted by the Induced Peptidyl-tRNA Drop-off.	Angewandte Chemie International Edition	50	2159-2161	2011
G Hayashi, (菅)	Ribosome evolution for two artificial amino acids in <i>E. coli</i> .	Chemistry&Biology	17	320-321	2010
Murakami Y, (深澤)	Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus lifecycle.	Microbes and Infection	15	45-55	2013
Arnaud N, (深澤)	Hepatitis C Virus Reveals a Novel Early Control in Acute Immune Response.	PLoS Pathogens	7(10)	e1002289, 1-17	2011
Yamamoto M, (深澤)	The structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen Virol	92(8)	2082-2087	2011

Shimizu S, (竹原)	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.	Int J Cancer	131	548-557	2012
Hikita H, (竹原)	Bak deficiency inhibits liver carcinogenesis: a causal link between apoptosis and carcinogenesis.	J Hepatol	57	92-100	2012
Hikita H, (竹原)	Delayed-onset caspase-dependent massive hepatocyte apoptosis upon Fas activation in Bak/Bax-deficient mice.	Hepatology	54(1)	240-251	2011
Hikita H, (竹原)	The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.	Hepatology	52(4)	1310-1321	2010
Shimizu S, (竹原)	The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.	J Hepatol	52	698-704	2010
Imakiire K, (宇都)	Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.	Mol Med Report	6 (2)	259-264	2012
Uto H, (宇都)	Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.	Hepat Mon	12 (2)	77-84	2012
Tamai T, (宇都)	Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for HCV-related hepatocellular carcinoma.	World J Gastroenterol	17(44)	4890-4898	2011
Oda K, (宇都)	Highly sensitive lens culinaris agglutinin-reactive $\alpha$ -fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.	Oncol Rep	26(5)	1227-1233	2011
Uto H, (宇都)	Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers.	Proteome Sci	8	70	2010
Takami Y, (宇都)	Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfonyl chloride isotope labeling method.	Hepatol Res	40(4)	438-445	2010

Kanmura S, (宇都)	The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma.	J Gastroenterol	45(4)	459-467	2010
Komase K, (前川)	Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.	Hepatol Res	-	-	(in press)
Sueki R, (前川)	Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.	J Med Virol	84(9)	1360-1368	2012
Shindo H, (前川)	IL-28B (IFN- $\lambda$ 3) and IFN- $\alpha$ synergistically inhibit HCV replication.	J Viral Hepat	AUG 7	AUG 7	2012
Maekawa S, (前川)	Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.	Hepatology	56(5)	1611-1621	2012
Miura M, (前川)	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis.	Hepatol Int	6(1)	386-396	2011
Shindo H, (前川)	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.	Hepatol Int	6(2)	482-490	2011
Kadokura M, (前川)	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.	PLoS One	6(9)	e24514	2011
Kadokura M, (前川)	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy.	Hepatol Int	5(3)	789-799	2011
Takaya D, (前川)	A new method for induced fit docking (genius) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.	Bioorg Med Chem	19(22)	6892-6905	2011
Kurosaki M, (前川)	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54(3)	439-448	2011

Enomoto N, (前川)	HCV genetic elements determining the early response to peginterferon and ribavirin therapy.	Intervirology	53(1)	66-69	2010
Itakura J, (前川)	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.	Biosystems	99(1)	70-78	2010
Sakamoto T, (村上)	Mechanism of the Dependence of Hepatitis B Virus Genotype G on Co-infection with Other Genotypes for Viral Replication.	J Viral Hepat	-	-	(in press)
Watanabe T, (村上)	Hepatitis C virus kinetics by administration of pegylated interferon- $\alpha$ in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.	Gut	-	-	(in press)
Ragheb M, (村上)	Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt.	J Med Virol	84(4)	587-595	2012
Sa-nguanmoo P, (村上)	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes.	Virus Research	158 (1-2)	209-215	2011
Piao G, (堀本)	A computational procedure for identifying master regulator candidates for diabetes progression in Goto-Kakizaki rat.	BMC Sys Biol	6(Suppl1)	S2	2012
Zhou H, (堀本)	Network Screening of Goto-Kakizaki Rat Liver Microarray Data during Diabetic Progression.	BMC Sys Biol	5(Suppl1)	S16	2011
Nakatsu M, (堀本)	Brute force meets Bruno force in parameter optimization: Introduction of novel constraints for parameter estimation by symbolic computation.	IET Sys Biol	5	281-292	2011
Saito S, (堀本)	Discovery of Chemical Compound Groups with Common Structures by a Network Analysis Approach.	J Chem Inf Model	51	61-68	2011

#### IV. 研究成果の刊行物・別刷

# Differentiation of Cancer Stem Cells

Taro Yamashita, Masao Honda and Shuichi Kaneko  
*Department of Gastroenterology,  
Kanazawa University Hospital Kanazawa, Ishikawa,  
Japan*

## 1. Introduction

Tumors originally develop from normal cells that acquire the ability to grow aberrantly and metastasize to distant organs (Hanahan and Weinberg, 2000). These malignant transformations are considered to be induced by the accumulation of multiple genetic/epigenetic changes (Yamashita et al., 2008b). Although considered monoclonal in origin, cancer is composed of heterogeneous cell populations. This heterogeneity is traditionally explained by the clonal evolution of cancer cells through a series of stochastic genetic events (clonal evolution model) (Fialkow, 1976; Nowell, 1976). In contrast, cancer cells and stem cells have similar capabilities with respect to self-renewal, limitless division, and the generation of heterogeneous cell populations. Recent evidence suggests that tumor cells possess stem cell features (cancer stem cells) to self-renew and give rise to relatively differentiated cells through asymmetric division, thereby forming heterogeneous populations (cancer stem cell model) (Clarke et al., 2006; Jordan et al., 2006). Accumulating evidence supports the notion that cancer stem cells can generate tumors more efficiently in immunodeficient mice than non-cancer stem cells in hematological malignancies and in various solid tumors (Al-Hajj et al., 2003; Bonnet and Dick, 1997; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 2004).

Cancer stem cells are considered to be resistant to chemotherapy and radiotherapy, which might be associated with the recurrence of the tumor after treatment (Boman and Huang, 2008; Dean et al., 2005; Diehn et al., 2009; Zou, 2008). These findings have led to the proposal of “destemming” cancer stem cells (Hill and Perris, 2007) in order to induce their differentiation into non-cancer stem cells or to eradicate cancer stem cells by inhibiting the signaling pathways responsible for their self-renewal. Recent studies have supported this proposal and suggest the utility of several factors to induce the differentiation of cancer stem cells and facilitate tumor eradication; however, it is still debatable whether the simple differentiation of cancer stem cells effectively eradicates tumors. Here, we summarize current knowledge on the differentiation of cancer stem cells and discuss the utility and limitation of differentiation therapy to eliminate cancer.

## 2. Cancer stem cell system

The consensus definition of a cancer stem cell is a cell within a tumor that possesses the capacity to self-renew and to generate the heterogeneous lineages of cancer cells that



comprise the tumor, as proposed by the AACR workshop in 2006 (Clarke et al., 2006). Thus, cancer stem cells can only be defined experimentally and their self-renewal ability is generally evaluated by the capacity of serially transplanted cells in immunodeficient mice. A cancer stem cell may give rise to one or two daughter cells that have essentially the same ability to replicate and generate differentiated non-cancer stem cells (Fig. 1 upper and lower left panels).




Fig. 1. Symmetric/asymmetric division of a cancer stem cell

Asymmetric cell division could be defined by the generation of one cancer stem cell and one progenitor cell with the loss of self-renewal capacity (Fig. 1 lower right panel). If both progenitors derived from a cancer stem cell lose the capacity of self-renewal by the induction of differentiation, the cancer stem cell population would be depleted and the tumor would subsequently shrink, according to the conventional cancer stem cell model.

## 2.1 Signaling pathways responsible for the self-renewal of cancer stem cells

A growing body of evidence suggests the similarities of normal stem cells and cancer stem cells in terms of their self-renewal and differentiation programs. Indeed, the self-renewal and differentiation programs in cancer stem cells are considered to be regulated by several signaling pathways that are activated in normal stem cells (Lobo et al., 2007). These signaling pathways seem to be activated during the process of normal organogenesis as well as carcinogenesis in a tissue-dependent manner (Pardal et al., 2003). Therefore, underscoring the significance of these signaling pathways on self-renewal and differentiation is critical for the development of treatment strategies specifically targeting cancer stem cells.



### 2.1.1 Wnt/ $\beta$ -catenin signaling

Wnt/ $\beta$ -catenin signaling has been studied primarily in developing embryos and was demonstrated to modulate cell proliferation, migration, and differentiation in a cellular context-dependent manner (Decaens et al., 2008; Giles et al., 2003; Moon et al., 2004; Ober et al., 2006). Wnt signaling is involved in the decision of stem cells to self-renew or differentiate during organogenesis, involving, for example, skin, intestine, bone marrow, kidney, and liver development (Moon et al., 2004; Thompson and Monga, 2007). Moreover, mutations of genes involved in Wnt/ $\beta$ -catenin signaling have been reported in a wide variety of human cancers including colorectal cancer, gastric cancer, skin cancer, ovarian cancer, liver cancer, and leukemia (Giles et al., 2003; Merle et al., 2005; Takebe et al., 2010; Tan et al., 2008; Vermeulen et al., 2010; Woodward et al., 2007; Zhao et al., 2007).

Wnt signaling is mediated through a core set of proteins to activate the transcriptional programs responsible for cell proliferation and development (Fig. 2). In the absence of Wnt proteins,  $\beta$ -catenin is phosphorylated and degraded by the Axin-APC-GSK3 $\beta$  complex. Once Wnt proteins bind to their receptor, Frizzled, the degradation complex is inactivated to stabilize  $\beta$ -catenin, which leads to its accumulation in the nucleus and interaction with T-cell factor (TCF) to activate the transcription of target genes (Moon et al., 2004).




Fig. 2. Wnt/ $\beta$ -catenin signaling. APC, adenomatous polyposis coli;  $\beta$ -cat,  $\beta$ -catenin; DSH, Dishevelled; Frz, Frizzled; GSK3, glycogen synthase kinase 3; TCF, T-cell factor

Recent studies have demonstrated that Wnt/ $\beta$ -catenin signaling also plays a role in the maintenance of cancer stem cells, including colorectal cancer (Vermeulen et al., 2010), breast cancer (Li et al., 2003; Woodward et al., 2007), and liver cancer (Yang et al., 2008). We have recently demonstrated that Wnt/ $\beta$ -catenin signaling augments self-renewal and inhibits the differentiation of liver cancer stem cells by the expression of the stem cell marker EpCAM, which results in the enrichment of the tumor-initiating cell population (Yamashita et al.,

2008a; Yamashita et al., 2009). We have further demonstrated that small molecules, which specifically inhibit the transcriptional activity of the TCF/ $\beta$ -catenin complex, can suppress the cell proliferation of EpCAM-positive liver cancer cell lines, suggesting the utility of these compounds for the eradication of cancers via the inactivation of Wnt/ $\beta$ -catenin signaling (Yamashita et al., 2007).

### 2.1.2 Hedgehog signaling

The Hedgehog signaling pathway was initially identified as a regulator of segmental patterning in *Drosophila* (Nusslein-Volhard and Wieschaus, 1980). Hedgehog signaling is activated in developing embryos, especially in the skeleton and neural tube, and regulates the cell proliferation, migration, and differentiation of stem cells (Varjosalo and Taipale, 2008). Several types of cancers are reported to have an activated hedgehog signaling pathway, including glioma (Clement et al., 2007), prostate cancer (Sanchez et al., 2005), breast cancer (Liu et al., 2006), pancreatic cancer (Li et al., 2007), and hematological malignancies (Zhao et al., 2009).

Hedgehog signaling is regulated by several proteins, including ligands (Sonic Hedgehog, Desert Hedgehog, and Indian Hedgehog), the Patched (Ptch) receptor, the Smoothened (Smo) transmembrane protein, and the zinc finger transcription factor Gli (Merchant and Matsui, 2010) (Fig. 3). In the absence of ligands, Ptch represses the activity of Smo and the Gli-mediated transcriptional program is constitutively suppressed (Gli-suppressed). Once ligands bind to Ptch, the repression of Smo is released and the Gli-mediated transcriptional program is activated (Gli-activated).




Fig. 3. Hedgehog signaling. Gli-C, Gli complex; Gli-A, Gli-activated; Hh, Hedgehog; Ptch, Patched; Smo, Smoothened

Accumulating evidence suggests that Hedgehog signaling regulates the self-renewal of cancer stem cells in several types of cancer, including glioblastoma and leukemia (Clement

et al., 2007; Zhao et al., 2009). Accordingly, Hedgehog signaling inhibitors have been clinically tested and might be beneficial for patients with advanced medulloblastoma or basal cell carcinoma, although Smo mutations in cancer cells confer resistance against such inhibitors (Rudin et al., 2009; Von Hoff et al., 2009; Yauch et al., 2009).

### 2.1.3 Notch signaling

Notch signaling has a pivotal role in regulating cell-to-cell communication during embryogenesis (Artavanis-Tsakonas et al., 1999), and is known to regulate stem cell fate in various organs (Androutsellis-Theotokis et al., 2006; Fre et al., 2005). Mammalian Notch ligands consist of the two structurally distinct families Delta-like ligands (DLLs) and Jagged ligands (JAGs), and these ligands are bound to the cell membrane (Fig. 4). The activation of Notch signaling is initiated by the binding of these membrane-bound ligands to Notch receptors, which results in the release of the Notch intracellular domain into the cytoplasm and nucleus by the  $\gamma$ -secretase complex to activate the Notch-specific transcriptional program.




Fig. 4. Notch signaling. DLL, Delta-like ligand; JAG, Jagged; NICD, Notch intracellular domain

Notch signaling has been implicated in various types of cancers, including solid tumors and leukemia (Pannuti et al., 2010). A growing number of recent studies has demonstrated that the activation of the Notch signaling pathway can drive tumor growth via the expansion of the cancer stem cell population (Korkaya and Wicha, 2009; Peacock and Watkins, 2008; Wilson and Radtke, 2006). Indeed, the Notch signaling pathway has been demonstrated to be active in cancer stem cells and to play a critical role in the self-renewal of cancer stem cells (Fan and Eberhart, 2008; Fan et al., 2010; Wang et al., 2009). Thus, Notch signaling is considered to be a good target for pharmacological inhibition to eradicate cancer stem cells, and the effect of Notch inhibitors against Notch, including  $\gamma$ -secretase inhibitors or monoclonal antibodies, have been extensively evaluated (Pannuti et al., 2010).

## 2.2 Signaling pathways responsible for cancer stem cell differentiation

Although self-renewal pathways are considered to be critical targets for the eradication of cancer stem cells, it is still debatable if differentiation pathways are equally effective for their

eradication. Several recent studies have provided evidence of the utility and limitation of the cancer stem cell differentiation strategy by modulating the signaling pathways responsible for the differentiation of normal stem/progenitor cells.

### 2.2.1 Bone morphogenic protein signaling

Bone morphogenic protein (BMP) signaling is known to be activated during embryogenesis and to play a pivotal role in the differentiation of neural and intestinal stem cells (Varga and Wrana, 2005). BMPs belong to a subgroup of the transforming growth factor- $\beta$  superfamily and activate signaling through the BMP-receptor (BMPR)-mediated phosphorylation of Smad proteins. Interestingly, recent studies have suggested the utility of BMPs to induce the differentiation of brain cancer stem cells and facilitate brain tumor eradication (Lee et al., 2008; Piccirillo et al., 2006). More recently, colorectal cancer stem cells have been shown to lack the expression of BMP4, and the administration of BMP4 enhanced the terminal differentiation, apoptosis, and chemosensitization of colorectal cancer stem cells (Lombardo et al., 2011). Interestingly, the effects of BMP4 on the differentiation of colorectal cancer stem cells appeared to be independent of the phosphorylation status of Smad, suggesting the importance of non-canonical signaling pathways activated by BMP4 for the differentiation of these cells.

### 2.2.2 Oncostatin M signaling

Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the IL-6 family, which includes IL-6, IL-11, and leukemia inhibitory factor (LIF). These cytokines share the gp130 receptor subunit as a common signal transducer, and activate Janus tyrosine kinases and the signal transducer and activator of transcription 3 (STAT3) pathways. However, gp130 forms a heterodimer with a unique partner, for example, the IL6 receptor, LIF receptor, or OSM receptor (OSMR); thus, each cytokine uniquely induces a certain signaling pathway (Heinrich et al., 2003), and OSM is known to exploit distinct signaling in an OSMR-specific manner (Kinoshita and Miyajima, 2002). Of note, OSM is known to activate the hepatocytic differentiation program in hepatoblasts in an OSMR-specific manner (Kamiya et al., 1999; Kinoshita and Miyajima, 2002).

We recently identified that OSMR is expressed in a subset of liver cancer stem cells (Yamashita et al., 2010). Interestingly, OSMR-positive hepatocellular carcinoma (HCC) was characterized by the abundant expression of stem cell markers and poorly differentiated morphology, suggesting that OSMR is more likely to be expressed in HCC with stem/progenitor cell features (Yamashita et al., 2008a). Of note, the OSM-OSMR signaling pathway was maintained in these HCCs, and OSM induced hepatocytic differentiation in liver cancer stem cells (Fig. 5).

Unexpectedly, we identified that the hepatocytic differentiation of liver cancer stem cells by OSM resulted in enhanced cell proliferation *in vitro* and modest anti-tumor activity *in vivo* when administered alone. However, we have further demonstrated that OSM-mediated hepatocytic differentiation of liver cancer stem cells effectively suppresses HCC growth when combined with conventional chemotherapy. It is possible that OSM may boost the anti-tumor activity of 5-FU by "exhausting dormant cancer stem cells" through hepatocytic differentiation and active cell division (Fig. 6). A similar chemosensitization effect was observed in colorectal cancer stem cells differentiated by BMP4 administration (Lombardo et al., 2011).




Fig. 5. Signaling pathways responsible for the self-renewal and differentiation of liver cancer stem cells. CSC, cancer stem cell; OSM, oncostatin M




Fig. 6. Effect of oncostatin M (OSM) on exhausting dormant liver cancer stem cells

### 3. Limitation of cancer stem cell differentiation

As described above, some of the signaling pathways for the differentiation of normal stem cells may be maintained in cancer stem cells. To induce the differentiation of cancer stem cells by specific ligands, the expression of the corresponding receptors bound to ligands is clearly required, suggesting the importance of clarifying the mechanisms for receptor expression regulation. Interestingly, BMPRs and OSMR were detected in colorectal and liver